PE20181521A1 - Composicion farmaceutica que comprende un potente inhibidor de urat1 - Google Patents

Composicion farmaceutica que comprende un potente inhibidor de urat1

Info

Publication number
PE20181521A1
PE20181521A1 PE2018001088A PE2018001088A PE20181521A1 PE 20181521 A1 PE20181521 A1 PE 20181521A1 PE 2018001088 A PE2018001088 A PE 2018001088A PE 2018001088 A PE2018001088 A PE 2018001088A PE 20181521 A1 PE20181521 A1 PE 20181521A1
Authority
PE
Peru
Prior art keywords
agent
pharmaceutical composition
powerful
cmax
composition including
Prior art date
Application number
PE2018001088A
Other languages
English (en)
Inventor
Wakeman Joanne Reiland
Colin Rowlings
Sha Liu
Gerry Burke
Corswant Christian Von
Christer Tannergren
Johan Hjartstam
Original Assignee
Ardea Biosciences Inc
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57517882&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20181521(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ardea Biosciences Inc, Astrazeneca Ab filed Critical Ardea Biosciences Inc
Publication of PE20181521A1 publication Critical patent/PE20181521A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se refiere a composiciones farmaceuticas que contienen acido 2-(( 3-( 4-cianonaftalen-1-il) piridin-4-il)tio )-2-metilpropanoico (denominado ¨Agente¨) de liberacion modificada, donde dicha composicion comprende un inhibidor de xantina oxidasa llamada febuxostat, despues de la administracion oral en ayunas a un sujeto produce una concentracion plasmatica maxima media geometrica (Cmax) del agente entre 1 ng/mL y 50 ng/mL, una relacion de Cmax/AUC0-24 entre 0,04 y 0,4, entre otros; donde la dosis del agente varia entre 0,5-20 mg. Dicha composicion farmaceutica es util para tratar trastornos del metabolismo del acido urico que incluyen policitemia, metaplasia mieliode, gota , entre otros
PE2018001088A 2015-12-08 2016-12-07 Composicion farmaceutica que comprende un potente inhibidor de urat1 PE20181521A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562264792P 2015-12-08 2015-12-08

Publications (1)

Publication Number Publication Date
PE20181521A1 true PE20181521A1 (es) 2018-09-24

Family

ID=57517882

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2018001088A PE20181521A1 (es) 2015-12-08 2016-12-07 Composicion farmaceutica que comprende un potente inhibidor de urat1

Country Status (20)

Country Link
US (3) US20180360761A1 (es)
EP (1) EP3386485A1 (es)
JP (2) JP6976946B2 (es)
KR (1) KR20180082613A (es)
CN (1) CN108289848A (es)
AU (1) AU2016368622B2 (es)
BR (1) BR112018011376A2 (es)
CA (1) CA3006167A1 (es)
CL (1) CL2018001510A1 (es)
CO (1) CO2018005842A2 (es)
EA (1) EA038828B9 (es)
HK (2) HK1253034A1 (es)
IL (1) IL259844B (es)
MA (1) MA43402A (es)
MX (1) MX2018006903A (es)
PE (1) PE20181521A1 (es)
PH (1) PH12018501236A1 (es)
SG (1) SG11201804100UA (es)
WO (1) WO2017097845A1 (es)
ZA (1) ZA201804519B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013067425A1 (en) * 2011-11-03 2013-05-10 Ardea Biosciences Inc. 3,4-di-substituted pyridine compound, methods of using and compositions comprising the same
TWI780270B (zh) * 2017-11-28 2022-10-11 靜岡縣公立大學法人 固體分散體
JP2022511380A (ja) * 2018-10-01 2022-01-31 アストラゼネカ・アクチエボラーグ 血清尿酸を低減させるための組成物
CN112057429B (zh) * 2019-06-11 2023-04-07 上海京新生物医药有限公司 雷西纳德控释药物组合物
CR20220069A (es) * 2019-07-16 2022-03-24 Astrazeneca Ab Composiciones farmacéuticas resistentes a la descarga de dosis que comprenden venirunad
CN113368073A (zh) * 2020-07-23 2021-09-10 太阳升(亳州)生物医药科技有限公司 制备用于降低血液尿酸水平的药物制剂的方法
CN113368032A (zh) * 2020-07-23 2021-09-10 太阳升(亳州)生物医药科技有限公司 药物组合物、口服固体制剂及其制备方法和用途
CN113368067A (zh) * 2020-07-23 2021-09-10 太阳升(亳州)生物医药科技有限公司 制备用于降低血液尿酸水平的口服药物片剂的方法
WO2022162021A1 (en) 2021-01-27 2022-08-04 Astrazeneca Ab Verinurad compositions and methods of use
KR20240055886A (ko) * 2021-09-17 2024-04-29 하이노바 파마슈티컬스 인코포레이티드 퀴놀린계 화합물의 서방성 정제 및 그 제조 방법
JP7515533B2 (ja) * 2022-04-28 2024-07-12 沢井製薬株式会社 デスロラタジン含有フィルムコーティング錠剤
WO2024076999A2 (en) * 2022-10-04 2024-04-11 Engrail Therapeutics, Inc. Gabaa receptor modulators and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2010416B2 (de) * 1970-03-05 1979-03-29 Hoechst Ag, 6000 Frankfurt Oral anwendbare Arzneiform mit Retardwirkung
JPH04234812A (ja) * 1990-03-16 1992-08-24 Yamanouchi Pharmaceut Co Ltd 持続性製剤用顆粒
CA2596392A1 (en) * 2005-02-15 2006-08-24 Wyeth Orally bioavailable cci-779 tablet formulations
KR20080041669A (ko) * 2005-07-28 2008-05-13 샤이어 엘엘씨 매일 단일 투여량 형태로 투여하기에 적합한 구안파신의약학적 제형물/조성물
US20090104266A1 (en) * 2005-09-15 2009-04-23 Tobias Jung 3-(2-dimethylaminomethylcy clohexyl)phenol retard formulation
WO2011126852A2 (en) * 2010-03-30 2011-10-13 Ardea Biosciences, Inc. Treatment of gout
PT2582683T (pt) * 2010-06-15 2018-05-25 Ardea Biosciences Inc Tratamento da gota e de hiperuricemia
AR081930A1 (es) * 2010-06-16 2012-10-31 Ardea Biosciences Inc Compuestos de tioacetato
WO2013067425A1 (en) * 2011-11-03 2013-05-10 Ardea Biosciences Inc. 3,4-di-substituted pyridine compound, methods of using and compositions comprising the same

Also Published As

Publication number Publication date
HK1253034A1 (zh) 2019-06-06
MA43402A (fr) 2018-10-17
US20210113472A1 (en) 2021-04-22
CO2018005842A2 (es) 2018-07-10
KR20180082613A (ko) 2018-07-18
EA038828B9 (ru) 2021-12-03
SG11201804100UA (en) 2018-06-28
JP2019501895A (ja) 2019-01-24
IL259844B (en) 2022-04-01
US20180360761A1 (en) 2018-12-20
JP6976946B2 (ja) 2021-12-08
AU2016368622A1 (en) 2018-06-07
EP3386485A1 (en) 2018-10-17
HK1256256A1 (zh) 2019-09-20
AU2016368622B2 (en) 2022-09-08
EA201891267A1 (ru) 2019-01-31
EA038828B1 (ru) 2021-10-26
US20230011269A1 (en) 2023-01-12
ZA201804519B (en) 2022-04-28
IL259844A (en) 2018-07-31
CL2018001510A1 (es) 2018-09-21
CN108289848A (zh) 2018-07-17
JP2022033758A (ja) 2022-03-02
CA3006167A1 (en) 2017-06-15
PH12018501236A1 (en) 2019-02-18
BR112018011376A2 (pt) 2018-12-04
WO2017097845A1 (en) 2017-06-15
MX2018006903A (es) 2018-11-09

Similar Documents

Publication Publication Date Title
PE20181521A1 (es) Composicion farmaceutica que comprende un potente inhibidor de urat1
ECSP23024864A (es) Formulación de vitamina d de liberación modificada y estabilizada y método de administración de la misma
CL2020000122A1 (es) Métodos de tratamiento para la fibrosis quística.
PE20170306A1 (es) Nuevas formas de dosificacion de liberacion modificada de un inhibidor de la xantina oxidorreductasa o de inhibidores de xantina oxidasa
AR122580A2 (es) Forma de dosificación de doxilamina y piridoxina y/o sus metabolitos o sales
PE20150974A1 (es) Derivados de piridina
EA202090029A1 (ru) Твердая композиция карипразина для орального введения
EA201691402A1 (ru) Фармацевтический препарат, содержащий соединение пиридиламиноуксусной кислоты
EA201691997A1 (ru) Производные 2,4-тиазолинидона в лечении расстройств центральной нервной системы
EA200971069A1 (ru) Метаболиты производных (тио)карбомоилциклогексана
CL2015003468A1 (es) Composicion solida para administracion oral conteniendo acido ibandronico o una sal farmaceuticamente aceptable del mismo y vitamina d.
MX2017016908A (es) Inhibidores de nadph oxidasa 4.
MA39443A1 (fr) Nouvelle formulation de méloxicam
MA46268A (fr) Dérivés de 5-[2-(pyridin-2-ylamino)-1,3-thiazol-5-yl]-2,3-dihydro-1h-isoindol-1-one et leur utilisation en tant qu'inhibiteurs doubles de phosphatidylinositol 3-kinase delta & gamma
MA38358A1 (fr) Formulations de composés organiques
PE20190972A1 (es) Combinacion de agonistas de fxr
PE20110943A1 (es) Formulacion oral solida de alisquireno
AR119318A1 (es) Un derivado de tetrahidroisoquinolina sustituido como modulador alostérico positivo de d1
CO6311076A2 (es) Una composición que comprende 2-n-butil-3-[4-(3-di-n-butilaminopropoxi)benzoil]-5-metilsulfonamido-benzofurano y sus sales aceptables farmacéuticamente
DOP2012000056A (es) Agente terapeutico para trastornos de ansiedad
AR111699A1 (es) Composición farmacéutica que comprende betahistina
CO2020005939A2 (es) Composiciones acuosas que comprenden bilastina y mometasona
BR112016029417A8 (pt) composição farmacêutica que compreende desmopressina, uso de uma ou mais gomas para aumentar sua estabilidade, película de desintegração oral e seu método de preparação
UY37426A (es) Método para producir una composición farmacéuticamente estable presentada como una solución acuosa
MY190202A (en) Pharmaceutical dosage forms containing sodium-1-[6-(morpholin-4-yl)pyrimidin-4-yl]-4-(1h-1,2,3-triazol-1-yl)-1h-pyrazol-5-olate